A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2013
12/05/2013	US20130323286 Synthesis of r-n-methylnaltrexone
12/05/2013	US20130323271 Nitric oxide donor neprilysin inhibitors
12/05/2013	US20130323268 Cytotoxic agents comprising new ansamitocin derivatives
12/05/2013	US20130323266 Methods for treating cancer with notch2/3 antibodies
12/05/2013	US20130323265 Methods for treating cancer with dll4 antagonists
12/05/2013	US20130323254 Therapeutic anti-tirc7 antibodies for use in immune related and other diseases
12/05/2013	US20130323239 Modulation of pilr receptors to treat sepsis
12/05/2013	US20130323232 Methods for the identification and treatment of patients sensitive to anti igf-1r inhbition therapy
12/05/2013	US20130323231 Treatment and prognosis of solid tumour cancers
12/05/2013	US20130323217 Compositions and methods for the controlled repopulation of gram-negative bacteria in the colon
12/05/2013	US20130323214 Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
12/05/2013	US20130323204 Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy
12/05/2013	US20130323203 Inhibitors of flaviviridae viruses
12/05/2013	US20130323199 Collagen material and method for producing collagen material
12/05/2013	US20130323187 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
12/05/2013	US20130323183 Absorbent dressings with painkilling activity
12/05/2013	US20130319411 Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
12/04/2013	EP2669272A1 Indole derivative and pharmacologically acceptable salt of same
12/04/2013	EP2669271A1 Indole derivative, and pharmacologically acceptable salt thereof
12/04/2013	EP2668953A1 Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis
12/04/2013	EP2667882A1 Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals
12/04/2013	EP2667878A1 Compositions and methods for cell transplantation
12/04/2013	EP2667877A2 Androgen composition for treating an ophthalmic condition
12/04/2013	EP2667875A1 Compositions comprising a prostaglandin for treating neuropsychiatric conditions
12/04/2013	EP2667872A2 Small molecule rnase inhibitors and methods of use
12/04/2013	EP2667871A1 Combinations
12/04/2013	EP2667865A1 Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
12/04/2013	EP2667715A1 Treatment of autism spectrum disorderes using glycyl-l-2-methylprolyl-l-glutamic acid
12/04/2013	EP2515897B1 A combination for the treatment of osteoarthritis
12/04/2013	CN203315381U Nanometer anti-AIDS (Acquired Immune Deficiency Syndrome) and anti-inflammatory medicament with radiotherapy function
12/04/2013	CN1480212B Application of neurotoxin therapy in treatment of urinary system and relative diseases
12/04/2013	CN103429238A Anticancer therapy with dual aurora kinase / MEK inhibitors
12/04/2013	CN103421738A Pharmacy applications of MTA1 and inhibitor thereof
12/04/2013	CN103417988A Application of CDK2 gene to preparation of leukemia induced differentiation therapeutic drug
12/04/2013	CN103417984A Nano dual-drug delivery system for targeting brain gliomas and preparation method thereof
12/04/2013	CN103417982A Application of human original longevity assurance gene 2 in preparation of drugs for improving sensitivity of breast cancer cells against anticancer drugs
12/04/2013	CN103417972A Cholesterol uptake inhibitor and vitamin-B composition and application thereof
12/04/2013	CN103417971A Dipeptidyl peptidase inhibitor and vitamin-B pharmaceutical composition and application thereof
12/04/2013	CN103417970A Application of estrogen up-regulation endothelial system protection molecule sphingosine-1-phosphate
12/04/2013	CN103417969A Regulator and pharmaceutical composition containing the same
12/04/2013	CN103417968A Application of poly cytosine binding protein-2 inhibitor to prepare medicaments for treating human glioma
12/04/2013	CN103417967A Application of inhibitor of CXCL-10 in preparation of drug for treatment and/or prevention of lung injury
12/04/2013	CN103417965A Anti-VEGF antibody containing pharmaceutical composition
12/04/2013	CN103417497A Oily drug controlled-release particles and preparation method of oily drug controlled-release particles
12/04/2013	CN103417469A Novel implant
12/04/2013	CN102686720B Method for inducing differentiation of dental pulp cells into odontoblasts
12/04/2013	CN101757623B 5-HT receptor agonist solid pharmaceutical composition
12/04/2013	CN101622243B Sulfonamide derivative
12/03/2013	US8598324 Anti-pathogen treatments
12/03/2013	US8598215 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
12/03/2013	US8598188 Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
12/03/2013	US8598171 Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders
12/03/2013	US8597958 IL1RL-1 as a cardiovascular disease marker and therapeutic target
12/03/2013	US8597697 Composition of beta-glucan and ashwagandha
12/03/2013	US8597665 Chimeric immunomodulatory compounds and methods of using the same-IV
12/03/2013	US8597654 Adjuvant therapy with an anti-ERBB2 antibody conjugated to a maytansiniod
12/03/2013	US8597604 Tricalcium phosphates, their composites, implants incorporating them, and methods for their production
12/03/2013	CA2474497C Compositions and methods related to tim-3, a th1-specific cell surface molecule
12/03/2013	CA2449426C Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/03/2013	CA2397207C Novel stra6 polypeptides
11/2013
11/28/2013	WO2013177594A2 Xylitol-based anti-mucosal compositions and related methods and compositions
11/28/2013	WO2013177505A1 Diabetes biomarkers
11/28/2013	WO2013177418A1 Methods of regulating cannabinoid receptor activity-related disorders and diseases
11/28/2013	WO2013176877A2 Treatment of addiction and impulse-control disorders using pde7 inhibitors
11/28/2013	WO2013176223A1 Pharmaceutical composition for treating inflammatory disease
11/28/2013	WO2013176220A1 Regulation of circadian rhythm
11/28/2013	WO2013175088A1 No/nitrogen gaseous mixture with a high no content for the treatment of severe hypoxemic respiratory failure
11/28/2013	WO2013175007A1 Agents for treating cystic fibrosis
11/28/2013	WO2013174997A1 Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies
11/28/2013	WO2013174847A1 Low -molecular -weight biotechnological chondroitin 6 - sulphate for prevention of osteoarthritis
11/28/2013	WO2013174767A1 A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
11/28/2013	WO2013174510A1 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
11/28/2013	WO2013174509A1 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
11/28/2013	WO2013174404A1 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
11/28/2013	WO2013174403A1 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
11/28/2013	US20130318648 Diagnosis and therapeutic epitope, and transgenic plant
11/28/2013	US20130317110 Compound, kinesin spindle protein inhibitor, and application thereof
11/28/2013	US20130317099 Picropodophyllin Polymorphs B or C for Use in Cancer Therapy
11/28/2013	US20130317094 Use of ellagitannins as inhibitors of bacterial quorum sensing
11/28/2013	US20130317089 Compositions and Methods Useful for Treatment and Prevention of Incontinence
11/28/2013	US20130317071 Novel compounds that are useful for improving pharmacokinetics
11/28/2013	US20130317047 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
11/28/2013	US20130317043 Compounds and Methods for Treating Autoimmune Diseases
11/28/2013	US20130317037 Method of administration and treatment
11/28/2013	US20130317036 Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
11/28/2013	US20130317033 Substituted triazolo-pyridazine derivatives
11/28/2013	US20130317032 Thiazole and thiadiazole compounds for inflammation and immune-related uses
11/28/2013	US20130317031 Nuclear Transport Modulators And Uses Thereof
11/28/2013	US20130317030 Methods for Diagnosis of Cardiovascular Disease
11/28/2013	US20130317024 Pyrrolopyrrolidinone compounds
11/28/2013	US20130317022 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
11/28/2013	US20130317021 Heterocyclic pyrimidine carbonic acid derivatives which are useful in the treatment, amelioration or prevention of a viral disease
11/28/2013	US20130317013 Ep4 receptor agonist, compositions and methods thereof
11/28/2013	US20130317008 Use of a Specific Cyclic Amine Derivative or the Pharmaceutically Acceptable Salts Thereof for the Treatment or Prevention of Heart Failure
11/28/2013	US20130317005 Non-hygroscopic salts of 5-ht2c agonists
11/28/2013	US20130317004 Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
11/28/2013	US20130317002 Fused pyrimidines
11/28/2013	US20130316994 Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
11/28/2013	US20130316989 Compositions and methods for the treatment of inflammatory disease
11/28/2013	US20130316987 Anti-Thrombotic Compounds

1 ... 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 ... 1151